Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05521074 · ClinicalTrials.gov registry record · NA
Transcranial Direct Current Stimulation Potentiation of Fear Extinction in OCD
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 86
- Enrollment target
NCT05521074: Completed NA study, sponsored by Massachusetts General Hospital.
NCT05521074 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 86 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05521074, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 86 participants
- Enrollment target
Study Summary
The investigators want to learn more about how human beings learn not to fear and the impact of changing the fear network in the brain using transcranial Direct Current Stimulation (tDCS) in individuals with obsessive compulsive disorder (OCD). The investigators hope this study will help us understand how future treatments can help patients with OCD better control unwanted fear.
Interventions
- DEVICE Sham tDCS
- DEVICE Active tDCS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2022-09-15 |
| Est. Completion | 2025-07-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05521074
The ClinicalTrials.gov registry entry for NCT05521074 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sham tDCS is the first listed.
NCT05521074 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05521074 about?
NCT05521074 is a clinical study titled "Transcranial Direct Current Stimulation Potentiation of Fear Extinction in OCD". The investigators want to learn more about how human beings learn not to fear and the impact of changing the fear network in the brain using transcranial Direct Current Stimulation (tDCS) in individuals with obsessive compulsive disorder (OCD). The investigators hope this study will help us understa...
What is the current status of trial NCT05521074?
This trial is currently completed. It is a NA study. The enrollment target is 86 participants. The study started on 2022-09-15. Estimated completion is 2025-07-31.
What interventions are being tested in trial NCT05521074?
The interventions under investigation include: Sham tDCS (DEVICE), Active tDCS (DEVICE).
Who is sponsoring clinical trial NCT05521074?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.